ClinicalTrials.gg
CompletedNCT03761225Updated Sep 29, 2023

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

A Phase 3 interventional study of Masitinib and Docetaxel in Metastatic Castrate Resistant Prostate Cancer, sponsored by AB Science. Completed at 9 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jun 2021.
  • Registered 4 years 2 months after the study started (first participant enrolled Sep 2014, registered Nov 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
714
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 338 studies in Prostatic Neoplasms with a site in Italy — 94 open to participants now, 142 under way, 36 of them phase 3. Prostatic Neoplasms · Italy.

Enrollment
66th of 243
714 · median 220
Started
2014
with 18 others
Phase 3
101 of 338
18 open now
Registered
144th of 338
by date

Among the 338 studies in Prostatic Neoplasms with a site in Italy, this one is the 66th largest by enrollment of the 243 interventional ones that give a count, is one of 19 that started in 2014, is one of 101 in phase 3, and was the 144th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

94 of the 338 studies in Prostatic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 338 studies in Prostatic Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.

Read the detailed description

The objective of this study is to evaluate the efficacy and safety of masitinib in combination with docetaxel and prednisone with respect to placebo in combination with docetaxel and prednisone in the treatment of first line metastatic Castrate Resistant Prostate Cancer (mCRPC). Approximately 580 patients will be randomized in 2 groups with a ratio 1:1. The primary outcome measure is progression free survival. Masitinib is a selective tyrosine kinase inhibitor that is thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment.

03

Conditions studied

  • Metastatic Castrate Resistant Prostate Cancer

Browse trials for

Keywords

  • metastatic castration-resistant prostate cancer
  • metastatic hormone-resistant prostate cancer
  • tyrosine kinase inhibitor
  • mCRPC
  • mHRPC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed Castrate Resistant Prostate Cancer (medical or surgical castration: androgens deprivation by GnHR agonist or antagonist or patient with surgical castration; hormonal castration confirmed biologically (testosterone \< 0.5ng/ml) with one of the following criteria:

    • Pre-treated with abiraterone with documented progressive disease, OR
    • Indicated for initiating docetaxel treatment (e.g., widespread visceral disease or rapidly progressive disease).
  2. Patient with evidence of progressive metastatic disease as assessed according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) recommendations.
  3. Patient with adequate organ function as per protocol

Exclusion criteria

Exclusion Criteria:

  1. Patient who has been previously treated with chemotherapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
714 participants (actual)

Study arms

  • Experimental
    Masitinib & docetaxel

    Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.

    Drug: Masitinib · Drug: Docetaxel · Drug: Prednisone

  • Placebo comparator
    Placebo & docetaxel

    Participants receive placebo (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.

    Drug: Docetaxel · Drug: Prednisone · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Progression Free Survival (PFS) is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Disease progression will be assessed according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) recommendations.

    Time frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.

    Time frame: From day of randomization to death, assessed for a maximum of 60 months

07

Study locations

9 sites
  • Centre Hospitalier Universitaire de Sherbrooke
    Sherbrooke, 13001, Canada
  • Polyclinique d'oncologie de Gentilly
    Nancy, 54100, France
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences
    Lucknow, 226014, India
  • Centro di Riferimento Oncologico
    Aviano, 33081, Italy
  • Istituto Europeo di Oncologia
    Milano, 20141, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56100, Italy
  • Universiti Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Clinical Oncology Dispensary
    Omsk, 644013, Russian Federation
  • Clinic Andros LLC
    St. Petersburg, 197136, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Dec 2020, 75 months.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 75 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2018
First posted
Dec 3, 2018
StartActual
Sep 2014
Primary completionActual
Dec 15, 2020
CompletionActual
Dec 15, 2020
Results delay requested
Jun 3, 2021
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03761225
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Dec 3, 2018
Start date
Sep 2014
Primary completion
Dec 15, 2020
Completion
Dec 15, 2020
Last update
Sep 29, 2023

Study contacts

Dominique Spaeth, MD
principal investigator · Polyclinique d'oncologie de Gentilly, Nancy, France

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion